ArticleFrontiers in surgery2026
Clinical features and outcomes of adult primary retroperitoneal lymphangioma: insights from a high-volume sarcoma center.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Giant Recurrent Retroperitoneal and Ischioanal Lymphangioma in an Adult: A Case Report.Reports (MDPI) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adult primary retroperitoneal lymphangioma (RPL) is an exceptionally rare benign vascular malformation. This study aims to elucidate the clinical presentation, imaging characteristics, management strategies, and long-term outcomes of this condition. Methods: We conducted a retrospective analysis of our prospectively maintained retroperitoneal tumor database at Peking University International Hospital (2014-2024). Inclusion criteria comprised adults (≥18 years) undergoing initial surgical resection with pathological RPL confirmation. Patients with other malignancies or recurrent disease were excluded. Comprehensive follow-up was performed to assess outcomes. Results: Among 28 enrolled patients (13 males, 15 females; median age 31 years), clinical presentation included incidental discovery (42.9%), abdominal discomfort (42.9%), lumbago (10.7%), and lower limb pain (3.6%). Preoperative imaging assessment was performed using Ultrasonography (US) (82.1%), computed tomography (CT, 100.0%), and magnetic resonance imaging (MRI, 14.3%). Characteristic CT findings typically included thin-walled multiloculated cystic masses with septal enhancement. All patients achieved R0/R1 resection, with 18 open and 10 laparoscopic procedures (2 conversions). Major complications occurred in 10.7% of cases (lymphatic leakage: 2; pancreatic fistula: 1), all resolving with appropriate management. Histopathological and immunohistochemical analysis confirmed lymphatic differentiation (D2-40: 100%; CD31: 89.3%; CD34: 84.6%). During median follow-up of 76 months, no recurrences or disease-specific mortality were observed. Conclusions: RPL represents a rare benign tumor frequently presenting with nonspecific symptoms. Complete surgical resection demonstrates excellent safety and long-term efficacy, with individualized approach selection based on tumor characteristics. Our findings from this substantial Chinese adult cohort provide valuable insights for managing this uncommon condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.